Weight Loss Drugs Listed By Health Insurers Aren’t Necessarily Covered

Eli Lilly’s obesity drugs are being added to major PBM formularies, making Zepbound and Foundayo coverable, but not necessarily covered by individual plans. The article says employer plans and Medicaid are still pulling back on obesity-drug coverage, while CMS’s BALANCE model has been delayed and Medicare beneficiaries will be able to pay $50 per month through a bridge program starting Jul. 1. DTC pricing remains far below list prices, with monthly costs ranging from $149 to $449 depending on product and dose.

Analysis

The key market misunderstanding is that formulary inclusion is a distribution event, not a demand event. For obesity drugs, the binding constraint remains plan sponsor willingness to absorb utilization risk, and that incentive is deteriorating as employers face budget pressure and see GLP-1 claims behaving like an uncapped specialty benefit. That means near-term upside to broad access is likely overstated, while the real beneficiaries are the manufacturers’ direct channels and any payer model that can pre-negotiate fixed out-of-pocket pricing.

For NVO, the marginal positive is not the formulary headline itself but the optionality it creates for lower-friction prescribing and longer persistence where coverage already exists. However, if plan sponsors continue tightening prior auth and eligibility, the volume lift from lower net prices may be modest versus consensus hopes, especially because the DTC channel still leaves a large affordability gap for most patients. The second-order effect is that payers will increasingly discriminate within the category, preferring the product with the lowest net cost and the easiest utilization controls rather than “covering obesity drugs” broadly.

The bigger catalyst horizon is 2027 planning and the July Medicare bridge program, both of which can move utilization but also create policy headlines that may reverse quickly if spending spikes. The BALANCE delay is a negative read-through for the whole category because it signals weak institutional appetite for expanding government-funded obesity coverage. Contrarian view: the market may be underestimating how much of the long-term value in NVO comes from indication expansion and cash-pay monetization rather than insurance penetration; at the same time, it may be overestimating how quickly commercial coverage will normalize.

Key Decisions for Investors

• Stay constructive on NVO but prefer selling put spreads over outright longs into the next 4-8 weeks: the stock has positive fundamental optionality, but the near-term lift from formulary news is likely capped by weak payer adoption.
• Pair trade: long NVO / short a basket of managed care names with obesity-benefit exposure over the next 3-6 months; if coverage remains selective, the drug maker captures incremental pricing power while payers absorb utilization pressure.
• For event-driven exposure, buy 6-12 month NVO call spreads rather than common stock; the setup is asymmetric if July bridge demand or 2027 employer renewals surprise positively, with limited premium at risk if coverage fails to broaden.
• Avoid chasing obesity-exposed healthcare suppliers on this headline alone; the real monetization path is still constrained by reimbursement, so any positive reaction should fade unless a named large employer or government sponsor expands coverage.
• Set a downside trigger on NVO if payer commentary turns more restrictive in upcoming benefits-season updates; that would signal the cash-pay channel is not enough to offset slower insured adoption.